AKT inhibitor (specialist)

Capivasertib

Brand names: Truqap

Capivasertib is an oral AKT (protein kinase B) inhibitor used with endocrine therapy for hormone-receptor-positive, HER2-negative advanced breast cancer harbouring relevant pathway alterations.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits all three isoforms of the serine/threonine kinase AKT, blocking PI3K/AKT/PTEN pathway signalling that drives tumour cell growth and survival.

Prescribing in practice

Hyperglycaemia can occur and may be severe; assess fasting glucose and HbA1c before starting and monitor during treatment, with caution in patients with diabetes.
Diarrhoea is common and should be managed promptly with antidiarrhoeals and dose modification.
Cutaneous reactions including rash can occur and occasionally require dose interruption.

Monitoring

Monitor blood glucose and for diarrhoea and skin reactions during treatment as directed by the SPC.

Counselling the patient

Report increased thirst, frequent urination or severe diarrhoea promptly.
Start antidiarrhoeal treatment at the first sign of loose stools and maintain good hydration.

Evidence & guidelines

NICE has appraised capivasertib with fulvestrant for advanced breast cancer, supported by randomised controlled trial evidence.

Reference: NICE TA evaluation; ESMO; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways